Levilactobacillus brevis KU15159对肠道功能和肠道活动在斯普拉格-道利大鼠的洛佩拉胺诱导便秘中的影响

相关实验视频

Updated: Jan 12, 2026

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Soyoung Jung¹, Yunjung Lee², Na-Kyoung Lee³

¹Department of Medical Nutrition, AgeTech-Service Convergence Major, Kyung Hee University, Gyeonggi 17104, Korea.

Preventive nutrition and food science

|November 3, 2025

概括

Levilactobacillus brevis KU15159有效地改善了肠道功能和大便在一个老鼠模式的便秘. 这种乳酸细菌菌株表现出抗氧化和抗炎作用,减少氧化应激和有害酶活性.

科学领域:

胃肠病学胃肠病学
微生物学微生物学
营养保健品营养保健品

背景情况:

便秘是一种普遍的胃肠道疾病,发病率越来越高.
乳酸细菌 (LAB) 以其调节肠道环境的潜力而闻名.
*Levilactobacillus brevis* KU15159对便秘的特定作用仍未得到充分研究.

研究的目的:

研究L. brevis* KU15159在小鼠模型中改善洛佩拉胺诱导的便秘的疗效.
评估 *L. brevis* KU15159 对肠道功能,排便,氧化应激和肠道酶活性的影响.

主要方法:

在Sprague-Dawley大鼠中使用loperamide建立便秘模型.
两周内使用*L. brevis* KU15159 (1×10^10 CFU/g) 或硫酸盐 (对照药物).
评估便指数,肠道过渡时间,DNA损伤,血氧化应激标志物和肠道有害酶活动.

主要成果:

与便秘组相比, *L. brevis* KU15159显著改善了便指数和缩短了肠道过境时间.
使用*L. brevis* KU15159可减少DNA损伤,血氧化应激和脂质过氧化物.
这种菌株显著抑制了肠道有害酶的活性,包括β-葡萄糖酶,缩酶和β-葡萄糖酶.

结论:

*L. brevis* KU15159在改善便秘方面显示出作为一种功能性食物的巨大潜力.
它的好处归因于增强肠道功能,改善排便,以及强大的抗氧化和抗炎性质.
这项研究支持使用*L. brevis* KU15159治疗便秘和促进肠道健康.

关键词:

这种细菌是Levilactobacillus brevis.肠道功能肠道功能便秘便秘便秘便秘洛佩拉米德是什么意思洛佩拉米德是什么意思

更多相关视频

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Probiotic Studies in Neonatal Mice Using Gavage

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...

Drugs Affecting GI Tract Motility: Other Laxatives

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...